In 1999 the US Department of Health and Human Services filed for, and was awarded, a patent (US6630507B1) for "Cannabinoids as antioxidants and neuroprotectants". The patent was written in such a manor that it encompasses natural and synthetic cannabinoids currently available and not yet studied.
The research used to apply for the permit included evidence of the folllowing:
- CBD has been found to have greater oxidative capacity than Vitamin C & Vitamin E.
- The way in which the CBD antioxidant reacts makes it useful "in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases".
- Cannabinoids as neuroportectants by limiting neurological damage after stroke or trauma.
- Therapeutic single doses up to 700mg showed no adverse affects when administered daily
Non-psychoactive CBD is particularly advantageous to use because it avoids toxicity that is encountered with psychoactive cannabinoids at high doses.
Legislation has changed significantly since 1999. In 2019 the patent expired. No company can lay claim to CBD. With the passage of the 2018 Farm Bill hemp has become a legal regulated USDA commodity.